# Project objectives:

To develop a comprehensive analysis of the overall policy landscape for cardiovascular diseases (CVDs) care and prevention, identifying gaps in policy and program implementation in South Korea. Understanding these policy and implementation gaps will serve to elevate public awareness of the growing CVD burden, support evidence-based policymaking, and encourage unified, multi-sectoral action for heart health in the Asia Pacific.

# Timelines:

* 1. Research on country profile & policy gaps: 11 July to 17 July

Please note: ACCESS Health will provide templates forall deliverables described below.

|  |
| --- |
| **Scope: Research on CVD policy landscape in South Korea for APAC CVD Alliance** |
| **Research on Country profile**  This initial research and analysis will contextualize the state of CVD in South Korea:  Conduct structured secondary research on Korean websites and portals using both peer reviewed and grey literature, including scientific articles, policy papers, and white papers or industry papers, with a focus on national policies, programs, and monitoring systems that address the various aspects of heart health. This includes searching on Korean news portal and Korean ministry websites for press releases on cardiovascular policy and programs both current and upcoming.  Identify gaps in policy & program implementation, monitoring, and evaluation. A template with specific questions will be provided for information capturing.  The areas these will fall in to areas follows:   1. **Monitoring and Evaluation Aspect:**    1. Health Promotion category       * Physical activity         + Are there regular audits of programs?       * Healthy Diet         + Are there regular audits of programs?       * CVD Awareness         + Are there any programs to monitor awareness of CVD at a periodic basis?         + Are any indicators being used to track CVD awareness?    2. Screening and Diagnosis category       * National screening programs         + What is the participation rate?         + What results have been achieved?         + Are there regular audits of programs?       * diagnostic capacity         + Is there a M&E plan around diagnostic capacity? What does it cover?       * Diagnostic Tests and Imaging         + Are there clinical guidelines on diagnostic tests and imaging that are revisited regularly? Are the tests prescribed in line with global standards of care?    3. Management of established CVD patients category       * Treatment & Acute care facilities         + Is there a M&E plan around treatment and acute care facilities? What does it cover? Are there regular audits of acute care facilities?       * Essential CVD medicines         + Is there an M&E plan around the availability and accessibility of essential medicines?       * Monitoring & rehabilitation         + Is there an M&E plan around rehabilitation centres, participation of patients over time and their success rate?       * Step down care         + Are there audits of step down care facilities - care standards, capacities, infrastructure?    4. System readiness category       * Availability of clinical registries         + Is there a long-term plan to integrate other sources of CVD patient data into registries? Is the data complete and useful/? What steps are being taken to improve the quality of data collection and analytics?       * clinical guidelines across healthcare setting         + Is there a body that regularly reviews clinical guidelines to ensure that they are up to date/in line with best practices applicable and tracking innovative therapies? How far are clinical guidelines followed in care-settings?       * integrated care         + Is data on 1-year mortality, hospital readmissions, prescriptions after stroke/heart failure being tracked?       * equitable access to CVD care         + Are there any government programs tracking the inclusivity of and equity in public health services?       * Health Financing         + Are insurance coverage plans reviewed on a regular basis to cover innovative therapies?       * CVD workforce         + Are there any government programs/audits evaluating the workforce -- capacity, capabilities and engaging in long-term resource planning?       * Supply Chain resilience category         + Are there any programs or bodies looking at building supply chain resilience into drugs, consumables, medical devices? Do they have a focus on CVD?       * Digital Health tools         + Is there a long-term plan for the integration of digital health systems and tools for the healthcare system and specifically for CVD care? 2. **Policy Aspect**    1. Health promotion category       * CVD Awareness         + Are there any on-the-ground efforts or policies to promote CVD awareness? What are the barriers resulting in a lack of CVD awareness among the public?    2. system readiness category       * integrated care         + Does the policy address integrating care across primary care, hospital and acute care settings along with the adoption of community-based programs?       * equitable access to CVD care         + Do policies address equitable access to CVD care? If yes, how?       * CVD workforce         + Are there any policy components addressing CVD workforce capacity building, task shifting, upskilling?       * Supply Chain resilience         + Do policies address supply chain resilience for drugs, diagnostics, consumables? How? 3. **Implementation Aspect**    1. system readiness category       * integrated care         + How far does policy translate into action? What types of initiatives have been put into place to support integrated care? What is their coverage? What are the gaps/challenges with implementing integrated care into this setting?       * CVD workforce         + How does the healthcare system fare when it comes to CVD workforce capacity and capability? What are the gaps and challenges?       * equitable access to CVD care         + What initiatives have been put into place for equitable CVD care?       * Supply Chain resilience         + What programs have been put in place to build supply chain resilience and what areas of CVD drugs and commodities do they cover? 4. **Future Plans for CVD**    1. Are there any future plans for CVD related policies/programs/initiatives even beyond Monitoring & Evaluation?    2. Are there any press releases or news about the government’s future plans for CVD-related policies/programs/initiatives? 5. **Determining the presence of a specific body/policies dedicated to CVD research**    1. Is there a specific program to encourage/build capacity in research on CVD? Is there a dedicated body driving this initiative?    2. how far is the government encouraging the training of healthcare professionals to conduct research on improving cardiovascular health?    3. how far is the government encouraging development of initiatives to empower citizens for self-care in cardiovascular health    4. how far is the government encouraging the incorporation of patient-reported outcomes and experiences into healthcare systems outcomes report    5. how far is the government encouraging identification of health systems gaps that can lead to CVD research and innovation    6. how far is the government promoting the development of R&D&I projects that address existing cardiovascular health needs and fostering collaboration across providers?    7. how far is the government encouraging epidemiological studies on differences in the prevalence of gender-based CVD or inequities    8. how much is the government supporting development of virtual care models to improve CVD patient outcomes? | |

**Compensation**

The total fee of USD 270 will be paid to the consultant upon completion of the deliverables and submission of an invoice to rajvi.mehta@accessh.org.

The payment shall be made from the parent Entity ACCESS Health International, INC from the dedicated account kept for ACCESS Health International Southeast Asia Ltd JP Morgan Bank USA.

**Term**

This engagement shall commence upon execution of this Agreement. The Agreement shall continue in full force and is effect from **July 11, 2023** to **July 17, 2023**.